Adolor commences clinical testing of its oral mu opioid receptor antagonist
September 05, 2017
"We are pleased with the outcome of this proof-of-concept trial as we continue to advance our pipeline of drug candidates with new mechanisms of action," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "These results further validate our genetic strategy to discover breakthrough treatments for human disease."
Top-line results from this study will be presented at the upcoming GASTRO 2009 conference in London on November 25, 2009 at 2:30 pm local time, included in the session entitled, "Therapeutic insights in functional digestive disorders."
Lexicon has three additional drug candidates progressing through Phase 2 clinical trials including LX1032, a peripherally-available TPH inhibitor for carcinoid syndrome, LX2931, an S1P lyase inhibitor for rheumatoid arthritis, and LX4211, an SGLT2 inhibitor for type 2 diabetes. Phase 2 clinical results from these programs are expected over the next 12 months.
SOURCE Lexicon Pharmaceuticals, Inc.